Learning Objectives:
1. Discuss the pathogenesis of ILD in systemic sclerosis.
2. Discuss the benefits and harms of nintedanib as a new FDA approved therapeutic option for ILD in systemic sclerosis.
Session date:
02/04/2020 - 8:30am to 9:30am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Patrick Onkka, M.D.